ADDvise extends the agreement with Laborie at a value of SEK 48 million

12-05-2023   Regulatory press release

ADDvise Group’s subsidiary Sonesta Medical AB extends the agreement with Laborie Medical Technologies (“Laborie”). The agreement is giving Laborie the right to sell Sonesta Medical’s urology- and gynecology patient positioning equipment and video fluoroscopy tables worldwide, with an exclusive right to distribute in USA and some European countries. Laborie commits to a minimum volume of SEK 48 million. The term of the agreement is two years. The total value of the orders during the term of the agreement is at least SEK 48 million.

Laborie is a leading global developer, manufacturer and distributor of medical technology and consumables used for diagnostic and therapeutic solutions in urology, urogynecology and gastroenterology. Laborie is a company based in Canada owned by Patricia Industries and a part of Swedish Investor AB.

Important information
This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 12 May 2023 at 08:40 CEST.

For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

About ADDvise Group
 ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

Latest press releases

Interim report 2025, January 1–March 31

Regulatory

In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational…

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…

ADDvise Group publishes annual report and sustainability report for 2024

Regulatory

Today, ADDvise Group AB (publ) is publishing the annual report and the sustainability report for 2024. Both reports are available on ADDvise’s website: www.addvisegroup.com. The annual report and the sustainability report are published in Swedish and English. The Swedish versions represent the originals. For further information, please contact: Staffan Torstensson, CEO +46 (0)70-433 20 19…